Regenerative Medicine Laboratory, Biotechnology Institute (BTI), Vitoria, Spain; Research and Development Department, University Institute for Regenerative Medicine and Oral Implantology-UIRMI (UPV/EHU-Fundación Eduardo Anitua), 01007 Vitoria, Spain.
Regenerative Medicine Laboratory, Biotechnology Institute (BTI), Vitoria, Spain; Research and Development Department, University Institute for Regenerative Medicine and Oral Implantology-UIRMI (UPV/EHU-Fundación Eduardo Anitua), 01007 Vitoria, Spain.
Ann Anat. 2023 Jun;248:152071. doi: 10.1016/j.aanat.2023.152071. Epub 2023 Feb 17.
The aim of the present work was to develop a fibrin membrane using plasma rich in growth factors (PRGF) technology with improved optical properties to be used for the treatment of ocular surface diseases.
Blood was drawn from three healthy donors, and the volume of PRGF obtained from each donor was divided into two main groups: i) PRGF or ii) platelet-poor plasma (PPP). Each membrane was then used pure or diluted to 90 %, 80 %, 70 %, 60 % and 50 %. The transparency of each of the different membranes was evaluated. The degradation and morphological characterization of each membrane was also performed. Finally, a stability study of the different fibrin membranes was performed.
The transmittance test showed that the fibrin membrane with the best optical characteristics was obtained after removal of platelets and dilution of fibrin to 50 % (50 % PPP). No significant differences (p > 0.05) were observed between the different membranes in the fibrin degradation test. The stability test showed that the membrane at 50 % PPP retains its optical and physical characteristics after storage at - 20 °C for 1 month compared to storage at 4 °C.
The present study describes the development and characterization of a new fibrin membrane with improved optical characteristics while maintaining mechanical and biological characteristics. The physical and mechanical properties of the newly developed membrane are preserved after storage for at least 1 month at - 20 °C.
本研究旨在开发一种富含生长因子的富血小板纤维蛋白膜(PRGF),以改善光学性能,用于治疗眼表疾病。
从 3 名健康供体中抽取血液,并将从每位供体中获得的 PRGF 体积分为两组:i)PRGF 或 ii)血小板贫乏血浆(PPP)。然后分别使用纯膜或稀释至 90%、80%、70%、60%和 50%的膜。评估了不同膜的透明度。还对每种膜的降解和形态特征进行了评价。最后,对不同纤维蛋白膜的稳定性进行了研究。
透光度测试表明,去除血小板并将纤维蛋白稀释至 50%(50% PPP)时,可获得具有最佳光学特性的纤维蛋白膜。在纤维蛋白降解试验中,不同膜之间无显著差异(p>0.05)。稳定性测试表明,与在 4°C 下储存相比,在-20°C 下储存 1 个月后,50% PPP 膜保持其光学和物理特性。
本研究描述了一种新型纤维蛋白膜的开发和特性,该膜具有改善的光学特性,同时保持机械和生物学特性。在-20°C 下储存至少 1 个月后,新开发膜的物理和机械性能得以保留。